Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 27 Lung Neoplasms 5 Brain Neoplasms 4 Esophageal Neoplasms 2 EGF-R Positive Non-Small Cell Lung Cancer 2 Adenocarcinoma of Lung 2 Squamous Cell Carcinoma of Lung 1 Plasma EGFR Mutation-positive Lung Cancer 1 Non-small Cell Lung Cancer Metastatic 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 NSCLC 1 Drug-Related Side Effects and Adverse Reactions 1 Bronchial Neoplasms 1 Breast Neoplasms 1

Interventions

Gemcitabine 53 Bevacizumab 52 Cyclophosphamide 49 Docetaxel 42 Carboplatin 40 pembrolizumab 37 Paclitaxel 36 Fluorouracil 36 Cisplatin 35 Radiotherapy 31 Oxaliplatin 31 Capecitabine 29 Irinotecan 28 Dexamethasone 27 Leucovorin 25 Cetuximab 25 Nivolumab 24 Doxorubicin 22 Drug Therapy 21 Erlotinib Hydrochloride 20 Pemetrexed 19 durvalumab 18 trametinib 17 fludarabine 16 atezolizumab 16 Trastuzumab 16 Sunitinib 16 Rituximab 16 Prednisone 16 Sorafenib 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × icotinib × Clear all

NCT03736837 2021-03-15

ALTER-L004

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡